Találati lista | Tudóstér

001-es BibID:	BIBFORM001208
035-os BibID:	PMID:17283584
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients / T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, Gy. Szegedi, E. Kiss
Dátum:	2007
Megjegyzések:	The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL- group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL- patients who met the Sapporo criteria. LAC was more common in the APS than the aPL- group (32.1% versus 9.9%, P < 0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL- group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban SLE antiphospholipid antibodies antiphospholipid syndrome primary prophylaxis thrombosis Primary prophylaxis acetylsalicylic acid beta2 glycoprotein 1 antibody cardiolipin antibody clopidogrel coumarin fibrinolytic agent lupus anticoagulant phospholipid antibody adult antiphospholipid syndrome article controlled study disease duration female follow up heart infarction human major clinical study male prevalence priority journal prophylaxis risk assessment risk factor stroke systemic lupus erythematosus thrombocytopenia thrombosis Adult Antibodies, Anticardiolipin Antibodies, Antiphospholipid Antibody Specificity Anticoagulants Antiphospholipid Syndrome Autoantigens beta 2-Glycoprotein I Cerebrovascular Accident Female Fibrinolytic Agents Follow-Up Studies Humans Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Aged Platelet Aggregation Inhibitors Risk Factors Thrombophilia Thrombosis egyetemen (Magyarországon) készült közlemény
Megjelenés:	Lupus 16 : 1 (2007), p. 39-45. -
További szerzők:	Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	elektronikus változat DOI Szerző által megadott URL
Borító:
Saját polcon: